Brian Armstrong, NewLimit co-founder (Stefan Wermuth/Bloomberg via Getty Images)
May 6, 2025 11:00 AM EDT
Financing

Bri­an Arm­strong’s NewLim­it rais­es a $130M Se­ries B, lay­ing out road map for an­ti-ag­ing drugs

Andrew Dunn

Senior Biopharma Correspondent

NewLim­it, an an­ti-ag­ing biotech start­up backed by Coin­base CEO Bri­an Arm­strong, has raised a $130 mil­lion Se­ries B round to get its lead drug can­di­dates …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

Trump, Con­gress look at match­ing some US drug prices to costs abroad

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

Ex­clu­sive: SEC ex­pect­ed to drop in­ves­ti­ga­tion of Il­lu­mi­na's $8B Grail deal

Eu­rope pledges €500M to at­tract glob­al sci­ence tal­ent

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times